Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$102.51 USD

102.51
9,365,005

-2.32 (-2.21%)

Updated Oct 31, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mark Vickery headshot

Medicare Drugs Targeted Under Inflation Reduction Act

by Mark Vickery

Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca

by Zacks Equity Research

Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.

Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.

Mark Vickery headshot

Markets Up Second-Straight Day; Lots of Data On Deck

by Mark Vickery

All major indices are up over the past week of trading, though are still underwater for the past month.

Merck (MRK), Eisai to End Keytruda-Lenvima Combo Cancer Study

by Zacks Equity Research

With the phase III LEAP-010 study failing to show an overall survival benefit for patients with recurrent or metastatic HNSCC, Merck (MRK) and Eisai have decided to close the study.

Sanghamitra Saha headshot

Oncology Market's Huge Potential Puts These Stocks in Focus

by Sanghamitra Saha

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan

by Zacks Equity Research

AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation

by Kinjel Shah

FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.

Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio

by Zacks Equity Research

Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.

Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study

by Zacks Equity Research

Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.

The Zacks Analyst Blog Highlights Merck, Philip Morris, Qualcomm, CVS Health and Chubb

by Zacks Equity Research

Merck, Philip Morris, Qualcomm, CVS Health and Chubb are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Merck, Philip Morris & QUALCOMM

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Philip Morris International Inc. (PM) and QUALCOMM Incorporated (QCOM).

Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?

by Zacks Equity Research

With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.

Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals

by Zacks Equity Research

Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

by Zacks Equity Research

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?

by Zacks Equity Research

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.

Sweta Killa headshot

Pharma ETFs in Focus Post Q2 Earnings

by Sweta Killa

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down. The stock climbs 9%.

Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View

by Zacks Equity Research

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View

by Zacks Equity Research

Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Merck (MRK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 5.07% and 4.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?